Wedbush Weighs in on TScan Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of TScan Therapeutics in a report issued on Wednesday, April 17th. Wedbush analyst D. Nierengarten expects that the company will earn ($0.26) per share for the quarter. Wedbush currently has a "Outperform" rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.04) per share. Wedbush also issued estimates for TScan Therapeutics' Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS and Q4 2025 earnings at ($0.27) EPS.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.08. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. The firm had revenue of $7.21 million for the quarter, compared to the consensus estimate of $2.94 million.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 7th.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX traded up $0.17 during mid-day trading on Thursday, hitting $6.92. The stock had a trading volume of 250,511 shares, compared to its average volume of 186,211. The company has a 50 day moving average of $7.02 and a two-hundred day moving average of $5.63. The firm has a market cap of $331.33 million, a PE ratio of -3.57 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51. TScan Therapeutics has a twelve month low of $1.62 and a twelve month high of $9.00.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pale Fire Capital SE acquired a new stake in TScan Therapeutics during the 3rd quarter worth about $42,000. Letko Brosseau & Associates Inc. purchased a new stake in shares of TScan Therapeutics during the 3rd quarter worth about $83,000. Virtu Financial LLC purchased a new stake in shares of TScan Therapeutics during the 4th quarter worth about $107,000. State Street Corp boosted its stake in shares of TScan Therapeutics by 60.4% during the 2nd quarter. State Street Corp now owns 38,500 shares of the company's stock worth $96,000 after acquiring an additional 14,500 shares in the last quarter. Finally, LPL Financial LLC purchased a new stake in shares of TScan Therapeutics during the 2nd quarter worth about $50,000. 82.83% of the stock is owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.